News Release

Phase II investigator-initiated clinical trial of RE-01 cell therapy for refractory ischemic (non-arteriosclerotic) lower extremity ulcers caused by Buerger's disease and collagen diseases initiated.

The key to azelaic acid lies in "how it's dissolved." A low-irritation serum formulation demonstrating acne-fighting efficacy comparable to a 20% cream has been established.

Rohto Pharmaceutical has published the "ROHTO Well-being Report - Integrated Report 2026".

Announcement Regarding the Acquisition of OP Biofactory as a Subsidiary

Supporting the establishment of the "General Incorporated Association for the Study of Ectopic Fat."

Azelaic acid is now available in a serum that makes it easy to incorporate into your daily skincare routine. "AZA Clear® Serum" is now available from the medical institution-exclusive brand "DRX®".

ロート製薬「藻活（もかつ）®プロジェクト」に参画

ロート製薬とイーダームが独占評価およびライセンスオプションに関する契約を締結

社内起業家支援制度「明日ニハ」が「ビジコンAWARDS 2026」にて審査員特別賞を受賞

セルビア共和国の化粧品代理店「Magic Cod d.o.o.」の持分取得（子会社化）に関するお知らせ